
NDRA Stock Forecast & Price Target
NDRA Analyst Ratings
Bulls say
ENDRA Life Sciences Inc. is poised for significant growth due to the anticipated FDA approval of its TAEUS technology, which offers a novel method for the early diagnosis and monitoring of liver diseases like NAFLD and NASH. The company's NPV analysis indicates a substantial upside potential for its stock, reflecting confidence in the marketability and practical application of its innovative diagnostic tools. Furthermore, TAEUS is expected to provide a more accurate and cost-effective alternative to existing technologies, enabling broader adoption and improved patient care in the healthcare landscape.
Bears say
ENDRA Life Sciences Inc reported a net loss of $1.2 million, translating to an earnings per share (EPS) of $(1.71), which reflects a deviation from earlier estimates of $(2.27). The company faces significant risks including liquidity concerns, the potential failure to demonstrate safety and efficacy for its product candidates in clinical trials, challenges in gaining regulatory approvals, and difficulties in commercialization and reimbursement. Additionally, the competitive landscape and macroeconomic factors may impact investor sentiment, contributing to a cautious outlook on the company’s financial stability and future performance.
This aggregate rating is based on analysts' research of ENDRA Life Sciences and is not a guaranteed prediction by Public.com or investment advice.
NDRA Analyst Forecast & Price Prediction
Start investing in NDRA
Order type
Buy in
Order amount
Est. shares
0 shares